6.1.2 WILLOW study (phase II clinical trial) 6.1.2.1 Study design and population The WILLOW study represented a pivotal Phase II clinical trial of brensocatib in bronchiectasis patients ( The study recruited 416 patients total, with 256 patients meeting inclusion criteria completing randomization, allocated to placebo group (87 patients), 10 mg brensocatib group (82 patients), and 25 mg brensocatib group (87 patients)
If the stopper is compromised, the sterility of your solution is at risk.
A friend suggested I look into Neurobion Forte Injection
If you have had Leber's disease (or other forms of optic nerve damage), an iron or folic acid deficiency, or low potassium, your doctor may not recommend it
For: Hospital, pharmacy, or clinical use only